Form 4: Biote Corp. Director Debra L. Morris Reports Stock Transactions

Director Debra L. Morris reports acquisition and disposal of Biote Corp. Class A Common Stock and Restricted Stock Units (RSUs).

Summary

• On May 21, 2024, Debra L. Morris, a director of Biote Corp., reported transactions involving the company's Class A Common Stock and Deferred Settlement Restricted Stock Units (RSUs).
• Morris acquired 9,110 shares of Class A Common Stock and disposed of the same amount.
• Following the reported transactions, Morris beneficially owns 39,110 shares of Class A Common Stock directly.
• Morris also acquired 10,395 Deferred Settlement RSUs, which are the economic equivalent of one share of Class A Common Stock each.
• Additionally, Morris acquired options to buy 65,258 shares of Class A Common Stock at an exercise price of $5.57, expiring on May 20, 2034.
• After these transactions, Morris holds 10,395 Deferred Settlement RSUs and options for 153,657 shares.
• The Deferred Settlement RSUs vest immediately but will be settled in either calendar year 2024 or 2025, or upon separation from service.
• The stock options vest on the earlier of May 21, 2025, or the day before the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continuous service.

Sentiment

Score: 5

Explanation: This is a neutral reporting of stock transactions by a company director, with no inherent positive or negative sentiment.

Future Outlook

Settlement of the Deferred Settlement RSUs will occur in either calendar year 2024 or 2025, or upon separation from service. Stock options vest on the earlier of May 21, 2025, or the day before the 2025 Annual Meeting, subject to continuous service.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities. It allows investors to monitor the actions of key personnel and their alignment with company performance.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The details provided are consistent with SEC requirements for disclosing changes in beneficial ownership.
• Comparable companies like Amgen, Gilead, and Regeneron also have similar insider transaction disclosures.

Stakeholder Impact

• The transactions may provide stakeholders with insights into the director's view of the company's prospects.
• The acquisition of stock options and RSUs aligns the director's interests with those of the shareholders.

Key Dates